Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

β-CATENIN stabilizes HIF2 through lncRNA and inhibits intravenous immunoglobulin immunotherapy

Frontiers in Immunology(2023)10.3389/fimmu.2023.1204907Source: DataRank Database

β-CATENIN stabilizes HIF2 through lncRNA and inhibits intravenous immunoglobulin immunotherapy is a research paper published in Frontiers in Immunology (2023). On theSindex it has a DataRank of 0.371. It has been cited 6 times, with 6 citing works in its 1-hop citation network.

N/A

0.371DataRank · unranked

Scored on demand from live citation data

Open Access6 citations · 6 citing works in its network

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (18 grants)Impact (FWCI 1.01)OA: goldTopics (47)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 79%Citation Network 21%

Base Score Contribution

0.292

From this paper's citation signal

Citation Network Contribution

0.0795

From 6 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 6 citers.

Adipose ADM2 ameliorates NAFLD via promotion of ceramide catabolism
Acta Pharmaceutica Sinica B20245 citations53 referencesContributes 0.034
Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials
Biomedicine & Pharmacotherapy202419 citations176 referencesContributes 0.017
ARID1A: Multiple functions in human pregnancy
Journal of Reproductive Immunology20252 citations70 referencesContributes 0.016
Long non-coding rnas as key modulators of the immune microenvironment in hepatocellular carcinoma: implications for Immunotherapy
Frontiers in Immunology20258 citations166 referencesContributes 0.013
Evolution and diversity of the hepatitis B virus genome: Clinical implications
Virology20249 citations222 referencesContributes 0.010

Authors (13)

Manjunatha Kadlera Nagaraj,Juan Carlos Hernandez ORCID,Dinesh Babu Uthay Kumar,Vivek Shukla,Risa Machida

Live enrichment

PubMed:37744383 PMC:PMC10516572 OpenAlex:https://openalex.org/W4386562983

NIAAA NIH HHS

Grant: P50 AA011999

NCATS NIH HHS

Grant: UL1 TR000130

NIDDK NIH HHS

Grant: P30 DK048522

NIAAA NIH HHS

Grant: R21 AA025470

NIAAA NIH HHS

Grant: R01 AA025204

NIAAA NIH HHS

Grant: R01 AA018857

NIAAA NIH HHS

Grant: R24 AA012885

NCATS NIH HHS

Grant: UL1 TR001855

NCI NIH HHS

Grant: P30 CA014089

National Institutes of Health

Grant: 3UL1TR001855-06A1S1

Southern California Clinical and Translational Science Institute

National Institutes of Health

Grant: 5R21AA025470-02

LncRNA with MSI2 and super-enhancer in liver cancer stem cells induced by alcohol

National Institutes of Health

Grant: 1R01AA025204-01A1

NANOG-positive cancer stem cells in liver oncogenesis induced by alcohol and HCV

National Institutes of Health

Grant: 5R24AA012885-25

Integrative Liver Cell Core

National Institutes of Health

Grant: 5P30DK048522-13

CORE-- CELL BIOLOGY

National Institutes of Health

Grant: 3UL1TR000130-05S2

Southern California Clinical and Translational Science Institute

National Institutes of Health

Grant: 3P50AA011999-12S1

Southern California Research Center for ALPD and Cirrhosis

National Institutes of Health

Grant: 1R01AA018857-01

Nanog-positive cancer stem cells in and liver oncogenesis by alcohol and HCV

National Institutes of Health

Grant: 3P30CA014089-17S1

USC COMPREHENSIVE CANCER CENTER (CORE) SUPPORT

FWCI

1.01

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.3389/fimmu.2023.1204907

publisherhttps://doi.org/10.3389/fimmu.2023.1204907

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1204907/full

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37744383

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10516572

Fields of Study

Hepatitis B Virus StudiesHepatocellular Carcinoma Treatment and PrognosisCancer Research and Treatments

MeSH Terms

Carcinoma, HepatocellularHumansImmunotherapyLiver NeoplasmsNeoplasm Recurrence, LocalLiver TransplantationImmunoglobulins, IntravenousLiving Donorsbeta CateninRNA, Long Noncoding

Keywords

Homeobox protein NANOGCateninCancer researchAntibodyWnt signaling pathwayImmunotherapyHBxImmunologyBiologyMedicineHepatitis B virusEmbryonic stem cellImmune systemSignal transductionCell biologyInduced pluripotent stem cell(Hcc) Hepatocellular Carcinoma(Den) Diethylnitrosamine(Fitc) Fluorescein Isothiocyanate(Hbig) Hepatitis B Immunoglobulin(Hbsag) Hepatitis B Surface Antigen(Hbv) Hepatitis B Virus(Tic) Tumor-Initiating CellCarcinoma, HepatocellularLiver NeoplasmsImmunoglobulins, IntravenousRC581-607Liver TransplantationLiving DonorsHumansRNA, Long NoncodingImmunologic diseases. AllergyNeoplasm Recurrence, Localbeta Catenin

Sustainable Development Goals

SDG 0: Good health and well-being

β-CATENIN stabilizes HIF2 through lncRNA and inhibits intravenous immunoglobulin immunotherapy

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (13)

Funding (18 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)